Please login to the form below

Not currently logged in

Excellence in Pre-Commercialisation Communications

Sponsored by

Back to results



by Bedrock Healthcare Communications for Hansa Biopharma

Summary of work

For any patient with end-stage kidney disease (ESKD), waiting for a donor kidney is a lengthy, draining and stressful process, adding to the mental and physical burden of the disease and dependency upon dialysis. For those patients who are ’highly sensitised’, and immunologically incompatible with most potential donors, ensuring a state of ‘transplant-readiness’ is even more challenging.

Hansa Biopharma is in the pre-commercialisation phase of a therapy that it is hoped will increase transplant eligibility among this highly sensitised population. Recognising an unmet need for comprehensive support for all ESKD patients through the renal transplantation journey, Hansa commissioned the trans*PLAN programme. This global, multilingual initiative provides a virtual Transplant Community Centre supported by a behavioural change programme, designed to enable patients to access a range of instructive, life-enhancing resources and take control of their own transplant journey.

We describe the developmental stage of trans*PLAN, representing a collaborative effort between Bedrock Healthcare Communications, Sprout Behaviour Change, Syneos Health and Backpack Health. A combination of international market research, analysis of published literature, beta testing of hosting technology and engagement of patient associations has supported the design of the trans*PLAN programme and laid the foundations for its implementation.

Judges' comments

Bedrock Healthcare Communications really made an effort to develop a thorough understanding of what they wanted to achieve. They showed a thorough identification of the clinical community and will clearly enhance HCP and patient experience of transplant over time. The judges look forward to seeing this project develop.


Keeping Maturation on Track. Raising Awareness of Erythroid Maturation Defect in Europe and Canada - by MediTech Media (a part of Nucleus Global) for Celgene – A BMS Company


trans•PLAN - by Bedrock Healthcare Communications for Hansa Biopharma

Category Sponsors

Dr Richard White, MP PhD, Oxford PharmaGenesis - Communiqué Judge

Key dates

Entry deadline 11 March 2022
Extended entry deadline 18 March 2022
(additional fee applies)
Judging days May 2022
Awards Ceremony 7th July 2022

Contact information:

For sponsorship opportunities:
Sales Team
Tel: +44 (0)1372 414200

General event enquiries:
Debbie Tuesley
Tel: +44 (0)1372 414243

Entry and dinner booking enquiries:
Saoirse Meenaghan
Tel: 01372 414253